Reversal of papilloma growth in rabbits therapeutically vaccinated against E6 with naked DNA and/or vesicular stomatitis virus vectors

Vaccine

Volumn 28, Issue 52, 2010, Pages 8345-8351

  Brandsma, Janet L ^a,b   Shlyankevich, Mark ^a   Su, Yuhua ^a   Zelterman, Daniel ^a,b   Rose, John K ^a,b   Buonocore, Linda ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

Author keywords

Antitumor immunity; CRPV; DNA vector; E6; Human papillomavirus; Prime boost; Therapeutic vaccine; Tumor growth; Vaccine; Vesicular stomatitis virus vector

Indexed keywords

UBIQUITIN FUSED COTTONTAIL RABBIT PAPILLOMAVIRUS E6 PROTEIN DNA VACCINE; UNCLASSIFIED DRUG; VIRUS VECTOR; WART VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CANCER PREVENTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; IMMUNE RESPONSE; NONHUMAN; PAPILLOMA; PRIORITY JOURNAL; RABBIT; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; FEMALE; GENETIC VECTORS; IMMUNIZATION, SECONDARY; ONCOGENE PROTEINS, VIRAL; PAPILLOMA; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RABBITS; SKIN NEOPLASMS; VACCINATION; VACCINES, DNA; VESICULOVIRUS;

EID: 78649752488     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.04.082     Document Type: Article

References (45)

1. Baseman J.G., Koutsky L.A. The epidemiology of human papillomavirus infections. J Clin Virol 2005, 32(Suppl. 1):S16-S24.
2. Schiffman M, Kjaer SK. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst 2003;Monographs(31):14-9.
3. Akgul B., Cooke J.C., Storey A. HPV-associated skin disease. J Pathol 2006, 208(2):165-175.
4. Hobbs C.G.L., Sterne J.A.C., Bailey M., Heyderman R.S., Birchall M.A., Thomas S.J. Human papillomavirus and head and neck cancer: a systematic review and meta-analysis. Clin Otolaryngol 2006, 31(4):259-266.
5. zur Hausen H. Papillomavirus infections-a major cause of human cancers. Biochim Biophys Acta 1996, 1288(2):F55-78.
6. Evans E.M., Man S., Evans A.S., Borysiewicz L.K. Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. Cancer Res 1997, 57(14):2943-2950.
7. Kanodia S., Fahey L.M., Kast W.M. Mechanisms used by human papillomaviruses to escape the host immune response. Curr Cancer Drug Targets 2007, 7(1):79-89.
8. Ressing M.E., van Driel W.J., Celis E., Sette A., Brandt M.P., Hartman M., et al. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A 0201-restricted E7-encoded epitope. Cancer Res 1996, 56(3):582-588.
9. Tindle R.W. Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer 2002, 2(1):59-65.
10. Gok M., Coupe V.M.H., Berkhof J., Verheijen R.H.M., Helmerhorst T.J.M., Hogewoning C.J.A., et al. HPV16 and increased risk of recurrence after treatment for CIN [see comment]. Gynecol Oncol 2007, 104(2):273-275.
11. Paraskevaidis E., Arbyn M., Sotiriadis A., Diakomanolis E., Martin-Hirsch P., Koliopoulos G., et al. The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treat Rev 2004, 30(2):205-211.
12. Sarkar A.K., Tortolero-Luna G., Follen M., Sastry K.J. Inverse correlation of cellular immune responses specific to synthetic peptides from the E6 and E7 oncoproteins of HPV-16 with recurrence of cervical intraepithelial neoplasia in a cross-sectional study. Gynecol Oncol 2005, 99(3 Suppl. 1):S251-S261.
13. Goodwin E.C., DiMaio D. Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways. Proc Natl Acad Sci U S A 2000, 97(23):12513-12518.
14. Welters M.J.P., de Jong A., van den Eeden S.J.F., van der Hulst J.M., Kwappenberg K.M.C., Hassane S., et al. Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. Cancer Res 2003, 63(3):636-641.
15. Welters M.J.P., van der Logt P., van den Eeden S.J.F., Kwappenberg K.M.C., Drijfhout J.W., Fleuren G.J., et al. Detection of human papillomavirus type 18 E6 and E7-specific CD4+ T-helper 1 immunity in relation to health versus disease. Int J Cancer 2006, 118(4):950-956.
16. de Jong A., van Poelgeest M.I.E., van der Hulst J.M., Drijfhout J.W., Fleuren G.J., Melief C.J.M., et al. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res 2004, 64(15):5449-5455.
17. Schlom J., Gulley J.L., Arlen P.M. Paradigm shifts in cancer vaccine therapy. Exp Biol Med 2008, 233(5):522-534.
18. Anderson R.J., Schneider J. Plasmid DNA and viral vector-based vaccines for the treatment of cancer. Vaccine 2007, 25(Suppl. 2):B24-B34.
19. Wu T.C. Therapeutic human papillomavirus DNA vaccination strategies to control cervical cancer [comment]. Eur J Immunol 2007, 37(2):310-314.
20. Cheng W.-F., Hung C.-F., Pai S.I., Hsu K.-F., He L., Ling M., et al. Repeated DNA vaccinations elicited qualitatively different cytotoxic T lymphocytes and improved protective antitumor effects. J Biomed Sci 2002, 9(6 Pt 2):675-687.
21. Haupt K., Roggendorf M., Mann K. The potential of DNA vaccination against tumor-associated antigens for antitumor therapy. Exp Biol Med 2002, 227(4):227-237.
22. Liu M.A., Ulmer J.B. Human clinical trials of plasmid DNA vaccines. Adv Genet 2005, 55:25-40.
23. Stevenson F.K., Rice J., Ottensmeier C.H., Thirdborough S.M., Zhu D. DNA fusion gene vaccines against cancer: from the laboratory to the clinic. Immunol Rev 2004, 199:156-180.
24. Brave A., Ljungberg K., Wahren B., Liu M.A. Vaccine delivery methods using viral vectors. Mol Pharmaceut 2007, 4(1):18-32.
25. Haglund K., Leiner I., Kerksiek K., Buonocore L., Pamer E., Rose J.K. Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteins. J Virol 2002, 76(15):7506-7517.
26. Lawson ND, Stillman EA, Whitt MA, Rose JK. Recombinant vesicular stomatitis viruses from DNA [erratum appears in Proc Natl Acad Sci U S A 1995 Sep 12;92(19):9009]. Proc Natl Acad Sci U S A 1995; 92(10):4477-81.
27. Kreider J.W., Bartlett G.L. The Shope papilloma-carcinoma complex of rabbits: a model system of neoplastic progression and spontaneous regression. Adv Cancer Res 1981, 35:81-110.
28. Dale C.J., Thomson S., De Rose R., Ranasinghe C., Medveczky C.J., Pamungkas J., et al. Prime-boost strategies in DNA vaccines. Methods Mol Med 2006, 127:171-197.
29. Woodland D.L. Jump-starting the immune system: prime-boosting comes of age. Trends Immunol 2004, 25(2):98-104.
30. Ramsay A.J., Kent S.J., Strugnell R.A., Suhrbier A., Thomson S.A., Ramshaw I.A. Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity. Immunol Rev 1999, 171:27-44.
31. Rose N.F., Roberts A., Buonocore L., Rose J.K. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1. J Virol 2000, 74(23):10903-10910.
32. Brandsma J.L., Shlyankevich M., Buonocore L., Roberts A., Becker S.M., Rose J.K. Therapeutic efficacy of vesicular stomatitis virus-based E6 vaccination in rabbits. Vaccine 2007, 25(4):751-762.
33. Brandsma J.L. The cottontail rabbit papillomavirus model of high-risk HPV-induced disease. Methods Mol Med 2005, 119:217-235.
34. Brandsma J.L., Shylankevich M., Su Y., Roberts A., Rose J.K., Zelterman D., et al. Vesicular stomatitis virus-based therapeutic vaccination targeted to the E1, E2, E6, and E7 proteins of cottontail rabbit papillomavirus. J Virol 2007, 81(11):5749-5758.
35. Brandsma J.L., Shlyankevich M., Zelterman D., Su Y. Therapeutic vaccination of rabbits with a ubiquitin-fused papillomavirus E1, E2, E6 and E7 DNA vaccine. Vaccine 2007, 25(33):6158-6163.
36. Leachman S.A., Shylankevich M., Slade M.D., Levine D., Sundaram R.K., Xiao W., et al. Ubiquitin-fused and/or multiple early genes from cottontail rabbit papillomavirus as DNA vaccines. J Virol 2002, 76(15):7616-7624.
37. Sundaram P., Tigelaar R.E., Xiao W., Brandsma J.L. Intracutaneous vaccination of rabbits with the E6 gene of cottontail rabbit papillomavirus provides partial protection against virus challenge. Vaccine 1998, 16(6):613-623.
38. Roediger E.K., Kugathasan K., Zhang X., Lichty B.D., Xing Z. Heterologous boosting of recombinant adenoviral prime immunization with a novel vesicular stomatitis virus-vectored tuberculosis vaccine. Mol Ther: J Am Soc Gene Ther 2008, 16(6):1161-1169.
39. Tan G.S., McKenna P.M., Koser M.L., McLinden R., Kim J.H., McGettigan J.P., et al. Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach. Virology 2005, 331(1):82-93.
40. Ramsburg E., Rose N.F., Marx P.A., Mefford M., Nixon D.F., Moretto W.J., et al. Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol. J Virol 2004, 78(8):3930-3940.
41. Egan M.A., Chong S.Y., Megati S., Montefiori D.C., Rose N.F., Boyer J.D., et al. Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus. AIDS Res Hum Retroviruses 2005, 21(7):629-643.
42. Schadeck E.B., Sidhu M., Egan M.A., Chong S.-Y., Piacente P., Masood A., et al. A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques. Vaccine 2006, 24(21):4677-4687.
43. Nicholls P.K., Stanley M.A. The immunology of animal papillomaviruses. Vet Immunol Immunopathol 2000, 73(2):101-127.
44. Stanley M.A. Immunobiology of papillomavirus infections. J Reprod Immunol 2001, 52(1-2):45-59.
45. Stern P.L. Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination. J Clin Virol 2005, 32(Suppl 1):S72-S81.